Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-07-24

Structure Therapeutics (GPCR)

Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$8,429,887
Raymond Stevens total, FY2025
CEO pay percentile vs peers
29:1
CEO-to-median pay ratio
96.24%
Say-on-pay support, latest vote
Companies that benchmark against GPCR
8 companies name GPCR as a compensation peer

Each company listed discloses GPCR in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named GPCR in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Raymond Stevens$672,094$0$2,387,996$4,846,926$508,871$0$14,000$8,429,887
Chief Executive Officer and Director
Jun Yoon530,53001,193,9982,423,463309,075010,5294,467,595
Chief Financial Officer
Blai Coll492,8130820,8661,666,117253,151014,0003,246,947
Chief Medical Officer
Xichen Lin505,3130567,1501,151,143257,103002,480,709
Chief Scientific Officer
Yingli Ma429,7680447,734908,788212,592001,998,882
Chief Technology Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY20242025
Raymond Stevens$8,429,887
Jun Yoon4,467,595
Blai Coll3,246,947
Xichen Lin2,480,709
Yingli Ma1,998,882

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Daniel G. WelchDirector2026-06-17A39,453$0$0Derivative, Class A CommonForm 4 ↗
Ted W. LoveDirector2026-06-17A39,45300Derivative, Class A CommonForm 4 ↗
Angus C. RussellDirector2026-06-17A39,45300Derivative, Class A CommonForm 4 ↗
Joanne WaldstreicherDirector2026-06-17A39,45300Derivative, Class A CommonForm 4 ↗
Sharon TetlowDirector2026-06-17A39,45300Derivative, Class A CommonForm 4 ↗
Eric DobmeierDirector2026-06-17A39,45300Derivative, Class A CommonForm 4 ↗
Xichen LinCHIEF SCIENTIFIC OFFICER2026-06-25A23,63408,036CommonForm 4 ↗
Xichen LinCHIEF SCIENTIFIC OFFICER2026-06-25D23,63400CommonForm 4 ↗
Xichen LinCHIEF SCIENTIFIC OFFICER2026-06-25A7,87800Derivative, Class A CommonForm 4 ↗
Xichen LinCHIEF SCIENTIFIC OFFICER2026-06-25D7,87849386,646Derivative, Class A CommonForm 4 ↗
Xichen LinCHIEF SCIENTIFIC OFFICER2026-06-25D23,63400Derivative, Class A CommonForm 4 ↗
Xichen LinCHIEF SCIENTIFIC OFFICER2026-07-14A23,63408,036CommonForm 4 ↗
Xichen LinCHIEF SCIENTIFIC OFFICER2026-07-14D6,27851318,895Derivative, Class A CommonForm 4 ↗
Xichen LinCHIEF SCIENTIFIC OFFICER2026-07-14D1,6005282,734Derivative, Class A CommonForm 4 ↗
Xichen LinCHIEF SCIENTIFIC OFFICER2026-07-14A7,87800Derivative, Class A CommonForm 4 ↗
Xichen LinCHIEF SCIENTIFIC OFFICER2026-07-14D23,63400CommonForm 4 ↗
Xichen LinCHIEF SCIENTIFIC OFFICER2026-07-14D23,63400Derivative, Class A CommonForm 4 ↗
FMR LLCGreater-than-10% holder2026-07-22D16,08550805,376Derivative, Class A CommonForm 4 ↗
FMR LLCGreater-than-10% holder2026-07-22D1,3675068,446Derivative, Class A CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Jun YoonRSU2025-03-15170,166$1,193,998
Xichen LinRSU2025-03-1580,829567,150
Raymond StevensRSU2025-03-15340,3322,387,996
Jun YoonOPTION2025-03-15413,4452,423,463
Xichen LinOPTION2025-03-15196,3861,151,143
Blai CollOPTION2025-03-15284,2411,666,117
Blai CollRSU2025-03-15116,988820,866
Raymond StevensOPTION2025-03-15826,8904,846,926
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Jun Yoon$1,193,998$0$2,423,4630.0%
Xichen Lin567,15001,151,1430.0%
Raymond Stevens2,387,99604,846,9260.0%
Blai Coll820,86601,666,1170.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Xichen LinOption100,0001.21
Xichen LinRSU28,539661,629
Jun YoonRSU116,9882,712,172
Yingli MaRSU12,231283,555
Xichen LinOption120,08711.75
Jun YoonRSU9,000208,650
Xichen LinRSU49,9651,158,355
Raymond StevensRSU78,5161,820,263
Yingli MaOption155,0407.02
Raymond StevensRSU101,0132,341,818
Xichen LinRSU80,8291,873,886
Xichen LinRSU64,2811,490,248
Jun YoonOption83,32811.75
Yingli MaRSU63,8101,479,329
Jun YoonRSU19,803459,100
Jun YoonRSU170,1663,945,015
Jun YoonOption31,2757.66
Jun YoonRSU34,668803,720
Yingli MaRSU27,549638,678
Yingli MaRSU21,408496,309
Jun YoonRSU26,646617,743
Jun YoonRSU3,99692,641
Raymond StevensOption826,8907.02
Jun YoonOption218,7755
Raymond StevensOption466,6875
Yingli MaOption400,0002.6
Jun YoonOption284,2417.02
Xichen LinOption196,3867.02
Raymond StevensOption188,71211.75
Jun YoonOption100,0001.21
Jun YoonOption76,31412.75
Yingli MaOption51,46811.75
Jun YoonOption18,56411.75
Jun YoonOption5,7602.79
Jun YoonRSU67,9501,575,308
Jun YoonOption413,4457.02
Raymond StevensRSU340,3327,890,030
Raymond StevensRSU44,8501,039,773
Jun YoonRSU44,6041,034,069
05

Incentive-plan design — the Compensation Discussion & Analysis

In designing our executive compensation program, the Compensation Committee and the Board are guided by the following philosophy and objectives: Attract and Retain Talent: Deliver competitive compensation at levels that attract, motivate and retain talented executives who contribute to the success of our business; Pay for Performance: Award compensation that motivates and rewards short- and long-term individual and company performance while discouraging excessive risk-taking; Alignment with Strategy: Provide incentives that motivate and reward the achievement of performance goals that directly correlate to the execution of our strategy and the enhancement of shareholder value, as well as to facilitate executive retention; and Alignment with Shareholders: Align our NEOs interests with those of our shareholders.

CEO STI target (% of salary)60%
CEO LTI target (% of salary)
Independent consultantAon
Clawback policyTrue
Anti-hedgingTrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-17158,547,4416,187,647212,69196.24%Passed
20252025-06-23115,026,06619,231,338101,02885.68%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-06-1796.24%a
20252025-06-2385.68%b

a. Approved under the standard stated in the filing — “Abstentions will be counted for the purpose of determining the presence or absence of a quorum, but will not be counted for the purpose of determining the number of votes cast on a given proposal.”.

b. Approved under the standard stated in the filing — “If final voting results are not available to us in time to file a Form 8-K within four business days after the Annual General Meeting, we intend to file a Form 8-K t Abstentions will be counted for the purpose of determining the presence or absence of a quorum, but will not be counted for the purpose of determining the number of votes cast on a given proposal.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)29 : 1
CEO total compensation$8,429,887
Median employee compensation$293,807
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Daniel G. WelchIndependent · Board Chair · Compensation · Nominating and Corporate Governance (Chair)$241,500$0$290,025$0$0$531,525
Sharon TetlowIndependent · Audit (Chair) · Nominating and Corporate Governance70,0000290,02500360,025
Ted W. Love, M.DIndependent · Compensation (Chair) · Research & Development67,5000290,02500357,525
Joanne Waldstreicher, M.DIndependent · Nominating and Corporate Governance · Research & Development (Chair)65,0000290,02500355,025
Eric DobmeierIndependent · Audit · Compensation62,5000290,02500352,525
Angus C. RussellIndependent · Audit55,0000239,80600294,806
Raymond Stevens, Ph.DEmployee director · Research & Development00000
09

Board fee structure and ownership guideline

Annual cash retainer$45,000
Annual equity retainer$290,025
Per board meeting fee
Committee chair fees (audit / comp / nom-gov)10,000 / 10,000
Stock ownership guideline
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$561,500
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$561,500

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Structure Therapeutics names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Structure Therapeutics.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Element2025Benjamin H. Gliklich$1,087,500$23,688,894$0$1,520,947$26,480,462
2Structure Therapeutics2025Raymond Stevens672,0942,387,9964,846,926508,8718,429,887

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Structure Therapeutics125%Options 67 · RSU 33NoAon
Element126%PSU 67 · RSU 33NoFW Cook

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Raymond StevensDEF 14A2026-04-230001104659-26-047740Section “Summary Compensation Table”. As printed: 8,429,887. Filing ↗machine: r1 · c47 · span 552927–552936
2Section 01, Jun YoonDEF 14A2026-04-230001104659-26-047740Section “Summary Compensation Table”. As printed: 4,467,595. Filing ↗machine: r4 · c47 · span 566755–566764
3Section 01, Blai CollDEF 14A2026-04-230001104659-26-047740Section “Summary Compensation Table”. As printed: 3,246,947. Filing ↗machine: r7 · c47 · span 580652–580661
4Section 01, Xichen LinDEF 14A2026-04-230001104659-26-047740Section “Summary Compensation Table”. As printed: 2,480,709. Filing ↗machine: r9 · c47 · span 590245–590254
5Section 01, Yingli MaDEF 14A2026-04-230001104659-26-047740Section “Summary Compensation Table”. As printed: 1,998,882. Filing ↗machine: r11 · c47 · span 599544–599553
6Section 03, Jun Yoon RSUDEF 14A2026-04-230001104659-26-047740Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t21 · r5 · c45 · span 637530–637539
7Section 03, Xichen Lin RSUDEF 14A2026-04-230001104659-26-047740Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t21 · r11 · c45 · span 664433–664440
8Section 03, Raymond Stevens RSUDEF 14A2026-04-230001104659-26-047740Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t21 · r2 · c45 · span 624101–624110
9Section 03, Jun Yoon OPTIONDEF 14A2026-04-230001104659-26-047740Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t21 · r6 · c45 · span 641844–641853
10Section 03, Xichen Lin OPTIONDEF 14A2026-04-230001104659-26-047740Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t21 · r12 · c45 · span 668745–668754
11Section 03, Blai Coll OPTIONDEF 14A2026-04-230001104659-26-047740Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t21 · r9 · c45 · span 655335–655344
12Section 03, Blai Coll RSUDEF 14A2026-04-230001104659-26-047740Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t21 · r8 · c45 · span 650998–651005
13Section 03, Raymond Stevens OPTIONDEF 14A2026-04-230001104659-26-047740Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t21 · r3 · c45 · span 628440–628449
14Section 07, pay ratioDEF 14A2026-04-230001104659-26-047740Section “CEO Pay Ratio”. As printed: 29 : 1. Filing ↗machine: span 980663–980665
15Section 08, Daniel G. WelchDEF 14A2026-04-230001104659-26-047740Section “Director Compensation”. As printed: 531,525. Filing ↗machine: t30 · r5 · c17 · span 1068679–1068686
16Section 08, Sharon TetlowDEF 14A2026-04-230001104659-26-047740Section “Director Compensation”. As printed: 360,025. Filing ↗machine: t30 · r3 · c17 · span 1064484–1064491
17Section 08, Ted W. Love, M.DDEF 14A2026-04-230001104659-26-047740Section “Director Compensation”. As printed: 357,525. Filing ↗machine: t30 · r2 · c17 · span 1062382–1062389
18Section 08, Joanne Waldstreicher, M.DDEF 14A2026-04-230001104659-26-047740Section “Director Compensation”. As printed: 355,025. Filing ↗machine: t30 · r4 · c17 · span 1066574–1066581
19Section 08, Eric DobmeierDEF 14A2026-04-230001104659-26-047740Section “Director Compensation”. As printed: 352,525. Filing ↗machine: t30 · r1 · c17 · span 1060301–1060308
20Section 08, Angus C. RussellDEF 14A2026-04-230001104659-26-047740Section “Director Compensation”. As printed: 294,806. Filing ↗machine: t30 · r6 · c17 · span 1070855–1070862
21Section 08, Raymond Stevens, Ph.DDEF 14A2026-04-230001104659-26-047740Section “Director Compensation”. As printed: 0. Filing ↗
22Section 02, Daniel G. Welch 2026-06-17Form 42026-06-180001206199-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
23Section 02, Ted W. Love 2026-06-17Form 42026-06-180001188919-26-000010Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, Angus C. Russell 2026-06-17Form 42026-06-180001534002-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, Joanne Waldstreicher 2026-06-17Form 42026-06-180001962413-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Sharon Tetlow 2026-06-17Form 42026-06-180001328565-26-000002Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Eric Dobmeier 2026-06-17Form 42026-06-180001202785-26-000004Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Xichen Lin 2026-06-25Form 42026-06-290001962926-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Xichen Lin 2026-06-25Form 42026-06-290001962926-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Xichen Lin 2026-06-25Form 42026-06-290001962926-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Xichen Lin 2026-06-25Form 42026-06-290001962926-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Xichen Lin 2026-06-25Form 42026-06-290001962926-26-000005Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Xichen Lin 2026-07-14Form 42026-07-150001962926-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Xichen Lin 2026-07-14Form 42026-07-150001962926-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Xichen Lin 2026-07-14Form 42026-07-150001962926-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Xichen Lin 2026-07-14Form 42026-07-150001962926-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Xichen Lin 2026-07-14Form 42026-07-150001962926-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Xichen Lin 2026-07-14Form 42026-07-150001962926-26-000006Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, FMR LLC 2026-07-22Form 42026-07-240001193125-26-315240Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, FMR LLC 2026-07-22Form 42026-07-240001193125-26-315240Insider equity transaction reported since the proxy statement. Filing ↗
41Section 06, 2026 voteForm 8-K2026-06-180001104659-26-075720Item 5.07 · say-on-pay result. As reported: 96.24% (votes for as printed: 158,547,441). Filing ↗
42Section 06, 2025 voteForm 8-K2025-06-250001104659-25-062576Item 5.07 · say-on-pay result. As reported: 85.68% (votes for as printed: 115,026,066). Filing ↗
43Section 03b vehicle mix (computed)ComputedcomputedRSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
44Section 09b board cost (computed)ComputedcomputedCash 561,500 + equity 0 + all other 0 = 561,500, summed across the director compensation table rows.machine: formula: Σ = 561,500
45Element, Section 10b CEO totalDEF 14A2026-03-230001590714-26-000034CEO total compensation as printed in Element's own proxy. As printed: 26,480,462. Filing ↗machine: r3 · c27 · span 596335–596345
46Structure Therapeutics (subject), Section 10b CEO totalDEF 14A2026-04-230001104659-26-047740CEO total compensation as printed in Structure Therapeutics's own proxy. As printed: 8,429,887. Filing ↗machine: r1 · c47 · span 552927–552936
47Section 10a, Element reciprocityDEF 14A0001590714-26-000034Element's most recent proxy was read; its disclosed peer group does not include Structure Therapeutics. Filing ↗